RefleXion to Present at 2024 Jefferies Global Healthcare Conference

June 4, 2024

HAYWARD, Calif., June 4, 2024 – RefleXion Medical, Inc., a theranostic external-beam radiotherapy company, today announced that Todd Powell, president and chief executive officer, Sam Mazin, Ph.D., founder and chief technology officer, and Sean Shirvani, M.D., chief medical officer will present an overview of the company and its breakthrough SCINTIX biology-guided radiotherapy at the Jefferies Global Healthcare Conference on Wednesday, June 5 at 8:30 a.m. EDT.

About RefleXion Medical

RefleXion is a privately held therapeutic oncology company located in Hayward, Calif., commercializing SCINTIX biology-guided radiotherapy, a novel therapy that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors. SCINTIX therapy is indicated for use in FDG-guided treatment of lung and bone tumors arising from either primary lung and bone cancers or resulting from metastases by other primary cancers. In addition to SCINTIX therapy, the RefleXion X1 is also FDA-cleared for conventional image-guided external-beam radiotherapy for solid tumors located anywhere in the body. For more information, please visit www.reflexion.com.